GSK plans to invest $30 billion in R&D and manufacturing in the U.S. in the next 5 years, with a new biologics flex factory in Pennsylvania. The company has seen 18 consecutive quarters of profitable growth since becoming a focused biopharma company in 2021.

In Q3, GSK reported GBP 8.5 billion in sales, up 8% from last year. Specialty Medicines saw a 16% increase in sales, with strong demand for Shingrix, Arexvy, and meningitis vaccines in Europe. The company is also navigating the impact of Medicare redesign from the IRA.

GSK’s RI&I sales were up 15% in Q3, driven by strong demand for products like Benlysta and Nucala. The company’s oncology portfolio also saw growth, with Jemperli and Ojjaara sales up 51% and 39% respectively. GSK is increasing its full-year specialty guidance from low teens to mid-teens percentage growth.

The company had a strong start for Nucala in COPD in Q3, with close to 1 out of every 2 prescriptions. GSK is confident in the potential of depemokimab, a long-acting IL-5 expected to launch early next year. The company sees significant room for growth in the biologic market for COPD patients.

GSK’s oncology portfolio is progressing well, with approval for BLENREP in 8 markets, including the U.S. The drug has shown superior efficacy compared to standard care daratumumab triplet, with a 51% reduction in the risk of death and a tripling of median progression-free survival. The U.S. approval is a significant step forward for patients. GSK’s BLENREP offers a novel treatment option for multiple myeloma patients, with a simplified REMS program making it easier for patients and healthcare providers to manage eye care. Expansion of clinical trials in the U.S. will support the use of BLENREP in earlier stages of the disease, promising meaningful advancements in treatment options.

Jemperli shows promise in rectal cancer treatment with a 100% complete response rate in Phase II trials. Additional studies are underway to explore its benefits for colon and head and neck cancer patients. GSK continues to advance its oncology pipeline, including the B7-H3 antibody drug conjugate GSK’227.

GSK’s HIV portfolio sees double-digit growth driven by strong demand for long-acting injectables and Dovato. Cabenuva, the first long-acting injectable HIV treatment regimen, experiences significant growth, with more than 75% of GSK’s growth coming from long-acting injectables.

Apretude, a long-acting prevention option, shows positive momentum in the U.S. with continued growth. Results from the CLARITY study comparing CAB LA for PrEP demonstrate high acceptability and preference among patients and healthcare providers. GSK upgrades its 2025 guidance to around 10% growth due to continued momentum in the HIV portfolio.

GSK’s industry-leading pipeline focuses on long-acting options for HIV treatment and prevention, anticipating a transition to ultra-long-acting regimens. Despite delays in trials, GSK remains on track to file in 2027 and launch innovative treatment options in 2028. The company aims to provide long-acting injectable treatment regimens for years to come, with plans for Q6M treatment and PrEP between 2028 and 2030. N6LS reported positive results in Phase IIb study for BRACE treatment and is now fully recruited for the next phase. GSK’s 2031 outlook does not include Q6M treatment for PrEP. In the Vaccines segment, sales increased due to strong demand for Shingrix, Arexvy, and Bexsero, with growth in Europe and Japan. Sales of Penmenvy in the U.S. were booked after the ACIP recommendation. Arexvy saw growth in Europe and international markets, but a decline in the U.S. due to slower market uptake. Trelegy sales drove growth in General Medicines, with the SITT class remaining strong. Expectations for Vaccines business are towards the top of guidance range. Core operating profit grew 11% driven by specialty portfolio growth. Operating margin improved by 90 bps in the quarter due to efficiency gains. Gross margin improved, reflecting benefits from the transition towards specialty products. Operating margin year-to-date is up 100 bps at constant exchange rates. GSK’s cash flow improved GBP 1.7 billion year-to-date, reaching GBP 6.9 billion, driven by increased operating profit and favorable provisions. Free cash flow rose GBP 1.8 billion, with Zantac payments totaling GBP 0.7 billion. Capital allocation remains disciplined, with shareholder distributions of GBP 3 billion and upgraded sales guidance to 6%-7%.

The company continues to invest in growth, with acquisitions and licensing agreements totaling GBP 3 billion. Operating profit and EPS guidance ranges have been raised to 9%-11% and 10%-12% respectively. Gross margin is expected to benefit from product mix, offset by supply chain charges in Q4. R&D investment is increasing ahead of sales.

Expectations for higher royalties of GBP 800 million to GBP 850 million have been raised. The tax rate is expected to be around 17.5%. Despite Q4 charges, GSK anticipates a fourth consecutive year of double-digit EPS growth. The company remains confident in its outlook to 2026 and ’31, with mitigation actions in place for tariffs.

GSK is focused on executing key asset launches and anticipates pivotal readouts across multiple opportunities next year. The FDA decision for depemokimab is expected in December. The company’s Q3 results demonstrate continued momentum, strong financial performance, and increased guidance for 2025. GSK is well-positioned for long-term growth and value creation for patients and shareholders. Emma Walmsley and Julie Brown discussed the company’s confidence in the short, medium, and long-term outlooks, focusing on oncology and RI&I. They highlighted upcoming data readouts and commercial execution as key factors. The team is optimistic about the future, with trigger points including BLENREP launch and upcoming data readouts for various products.

Regarding the outlook for 2026, Emma Walmsley reiterated the team’s high confidence in both short and long-term forecasts. The company is on track to exceed its initial guidance of $33 billion by 2031. Luke Miels expressed confidence in the number 40 and emphasized the doability of the forecasted products.

Luke Miels provided insights on the growth of Shingrix ex U.S., highlighting a 3-stage strategy focused on penetration and targeting high-risk subgroups. The company is seeing encouraging results in Europe and Japan, with an average immunization rate of around 10% in the top 10 markets ex U.S.

Questions from analysts focused on the performance of Shingrix and margin leverage. Luke Miels addressed the growth prospects of Shingrix ex U.S., emphasizing the strategy to maintain pricing discipline and build evidence of the launch in key markets. Julie Brown discussed the company’s drive for meaningful SG&A leverage and the impact of launches like depemokimab and Nucala COPD on OpEx. The company plans to expand populations in countries and pivot to emerging markets with pricing flexibility. Despite challenges in China, focus on comorbid is resonating. Confidence in reaching a 31% margin target by ’26. Investment in R&D and new launches is a priority for growth. Productivity benefits are being driven through operating model cost and technology modifications.

Technology is changing sales and marketing strategies in the industry. Updates on depemokimab access and BLENREP label debate. Experience with BLENREP in Europe has been positive, with a focus on supporting physicians. Close to 8,000 patients globally have been exposed to BLENREP. Competitive environment for depemokimab, with a focus on access strategy. Opportunity for ATP-driven administration with long dosing intervals and strong efficacy.

Clear opportunity for ATP-driven administration with long dosing intervals and strong efficacy for depemokimab. Market research indicates high potential for product success. Strategy to focus on new patients going on biologics. Significant reduction in attacks causing hospitalization and cost benefits for healthcare systems in asthma treatment. Emma Walmsley and Deborah Waterhouse discussed GSK’s long-acting portfolio and business development progress in a recent call. Despite delays in a Phase III study for Q4M, Cabenuva’s strong performance has boosted HIV guidance. GSK remains confident in their pipeline and strategic partnerships, emphasizing continued focus on innovation and growth. GSK executives discussed their strategic approach to key assets, highlighting successful market share gains in Nucala COPD. The company remains committed to the U.S. market, emphasizing engagement with the administration and continued investment in innovation. Updates on IRA negotiations and the potential launch of LEN plus islatravir in 2027 were also provided.

Deborah Waterhouse shared insights on the expected launch of LEN plus islatravir in 2027, emphasizing the importance of integrase inhibitors in HIV treatment regimens. GSK remains confident in its ability to drive growth in the HIV business, despite competitive challenges. The company’s focus on innovation and strategic positioning underpins its outlook for the future.

Analysts raised questions about GSK’s peak sales estimates and revenue targets for key products, seeking clarity on factors influencing the EUR 40 billion target. Executives reiterated their commitment to delivering on long-term goals, with a detailed outlook for 2026 expected next year. Discussions also touched on the evolving landscape of HIV treatment and the market potential for long-acting injectables. Deborah Waterhouse discusses patient willingness to take long-acting HIV regimens, with 30% willing to take Q4M and 50% willing to take Q6M. Different physicians prefer different intervals, but market expansion is expected with the introduction of new medicines like VH184 and N6LS for Q6M.

Luke Miels expresses confidence in late-stage assets like BLENREP, anticipating a significant impact in the next few years. Updates on launches and competition are expected next year. The focus is on the initial launch and the pathway to second-line treatments.

Sarita Kapila asks about the rollout of Nucala in COPD and the momentum of Jemperli in endometrial cancer. GSK is seeing broad uptake of Nucala and strong resonance among pulmonologists. Jemperli has shown promise in endometrial cancer, with ongoing studies in rectal cancer and head and neck cancer.

Tony Wood highlights GSK’s progress in endometrial cancer with Jemperli, the first drug with dual primary endpoints. Studies like DOMENICA and AZUR-1 are evaluating new treatment regimens. Ongoing studies in colon cancer and head and neck cancer are expected to provide results in ’28. GSK executives discuss the success of Jemperli and the growth of their COPD portfolio, with Phase III studies underway. They also highlight market share gains against pembrolizumab. Plans for BLENREP growth and general medicines development are outlined, with a focus on oncology opportunities. CEO Emma Walmsley expresses gratitude and confidence in GSK’s future under new leadership. The latest Stock Advisor top 10 list features stocks with potential for high returns. Historical examples include Netflix and Nvidia, which had staggering returns. Stock Advisor boasts an average return of 894%, outperforming the S&P 500. Don’t miss out on the latest top 10 picks with Stock Advisor.

This article is a transcript of a conference call by The Motley Fool. While efforts are made for accuracy, errors may occur. The Motley Fool advises conducting personal research and reviewing SEC filings. The Motley Fool recommends GSK and has a disclosure policy. Visit the link for the GSK Q3 2025 Earnings Call Transcript.

Read more at Yahoo Finance: GSK (GSK) Q3 2025 Earnings Call Transcript